The global infectious disease testing market size was valued at USD 28 billion in 2025 and is projected to grow from USD 29.96 billion in 2026 to USD 51.48 billion by 2034, registering a CAGR of 7% during the forecast period from 2026 to 2034. North America dominated the infectious disease testing market with a market share of 41.2% in 2025.
Infectious disease testing involves diagnostic methods used to detect bacteria, viruses, fungi, parasites, and other disease-causing pathogens in clinical samples. These tests play a vital role in early diagnosis, disease surveillance, treatment selection, and infection control across healthcare settings. Demand is driven by the rising prevalence of infectious diseases, growing awareness of preventive healthcare, advancements in molecular diagnostics, and increasing investments in public health infrastructure.
Download a Free Sample To learn more about this report,
Growing Adoption of Multiplex Molecular Testing
The infectious disease testing market is increasingly shifting toward multiplex molecular platforms capable of detecting multiple pathogens or targets from a single patient sample. These systems can shorten diagnostic workflows when symptoms overlap across different infections and can help clinicians distinguish between bacterial, viral, and other infectious causes. Broader multiplex capability is therefore increasing the clinical value of molecular testing in hospitals and diagnostic laboratories.
In June 2024, the U.S. Food and Drug Administration authorized a multiplex molecular test capable of simultaneously detecting and differentiating respiratory viruses including influenza A, influenza B, respiratory syncytial virus, and SARS-CoV-2.
Increasing Use of Point-of-Care Infectious Disease Testing
Infectious disease testing is increasingly moving closer to patients through point-of-care platforms that can deliver diagnostic results during a clinical visit. Faster testing can support earlier treatment decisions and reduce dependence on centralized laboratories for selected infections. This is particularly valuable in urgent-care, primary-care, emergency, and resource-limited settings where rapid clinical decisions are required.
In September 2024, the U.S. Food and Drug Administration authorized a point-of-care molecular test for influenza A and B and respiratory syncytial virus that provides results in approximately 15 minutes.
Increasing Global Burden of Infectious Diseases
The continued occurrence of infectious diseases creates sustained demand for diagnostic testing across hospitals, laboratories, public-health agencies, and community healthcare settings. Accurate testing supports disease identification, treatment selection, surveillance, and outbreak control. Persistent infectious disease activity therefore provides a fundamental source of demand for diagnostic technologies.
In June 2025, the World Health Organization reported that an estimated 304 million people required treatment for neglected tropical diseases in 2024, demonstrating the continuing global burden of infectious diseases requiring diagnosis and management.
Limited Diagnostic Infrastructure in Low-Resource Settings
Access to infectious disease testing remains constrained in regions with limited laboratory infrastructure, shortages of trained personnel, inconsistent electricity or connectivity, and restricted access to diagnostic equipment. These limitations can prevent timely testing even when suitable technologies exist. Infrastructure gaps therefore restrict the penetration of advanced infectious disease diagnostic platforms.
In October 2024, the World Health Organization reported that many countries continued to face significant gaps in access to quality-assured diagnostics, particularly in lower-resource healthcare systems.
Expansion of At-Home Infectious Disease Testing
The development of simple tests that can be performed outside traditional healthcare facilities creates opportunities to expand infectious disease screening and diagnosis. At-home testing can improve convenience, increase access for individuals who may not immediately visit a healthcare provider, and support earlier identification of selected infections. Regulatory acceptance of reliable self-testing technologies can further expand this opportunity.
In March 2025, the U.S. Food and Drug Administration authorized an over-the-counter combination test for influenza A and B and COVID-19, expanding access to infectious disease testing without requiring a prescription or laboratory visit.
Antimicrobial Resistance Increases the Need for Accurate Pathogen Identification
The spread of antimicrobial resistance makes it increasingly important to determine the causative pathogen and, where appropriate, its susceptibility to available treatments. Diagnostic uncertainty can contribute to inappropriate antimicrobial use and delay effective therapy. Testing developers therefore face the challenge of providing sufficiently rapid and accurate information to support antimicrobial stewardship without adding excessive complexity to clinical workflows.
In April 2025, the World Health Organization reported that approximately one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments, underscoring the growing importance of effective diagnostic information.
Kits & Reagents Segment Dominated the Market with 62.8% Share in 2025
The kits & reagents segment dominated the global infectious disease testing market with a 62.8% share in 2025, driven by their widespread use in routine diagnostic testing, disease surveillance, and laboratory screening. Growing demand for rapid, accurate, and high-throughput diagnostic solutions, along with the increasing prevalence of infectious diseases, continues to strengthen the segment's leading position.
The instruments and software segments are witnessing steady growth as healthcare providers and diagnostic laboratories increasingly adopt automated testing platforms and digital diagnostic solutions. Rising investments in laboratory modernization, workflow automation, and data management systems are supporting demand across both segments.
Continuous technological advancements in diagnostic equipment, artificial intelligence-based analytics, and laboratory information management systems are expected to further enhance testing efficiency. The growing emphasis on early disease detection and integrated diagnostic workflows continues to create opportunities for both instruments and software solutions.
Request Customizationto receive a tailored report.
Immunodiagnostics Segment Dominated the Market with 44.6% Share in 2025
The immunodiagnostics segment dominated the global infectious disease testing market with a 44.6% share in 2025, supported by its extensive use in detecting bacterial, viral, and parasitic infections through antibody and antigen testing. The technology's rapid turnaround time, high reliability, and widespread availability continue to make it a preferred choice in hospitals and diagnostic laboratories.
The PCR and DNA sequencing & NGS segments are witnessing significant growth as molecular diagnostic techniques become increasingly important for identifying pathogens with greater speed and precision. Expanding applications in outbreak monitoring, antimicrobial resistance testing, and precision diagnostics are driving adoption across both technologies.
Continuous improvements in sequencing platforms, multiplex PCR assays, and genomic surveillance capabilities are expected to further strengthen these segments. Increasing investments in advanced molecular diagnostics are supporting the development of more accurate and comprehensive infectious disease testing solutions.
Hospitals/Clinical Laboratories Segment Dominated the Market with 48.3% Share in 2025
The hospitals/clinical laboratories segment dominated the global infectious disease testing market with a 48.3% share in 2025, driven by the high volume of diagnostic testing performed for infectious diseases in both inpatient and outpatient settings. Increasing patient admissions, expanding laboratory infrastructure, and the need for timely diagnosis continue to support the segment's leading position.
The reference laboratories and physician offices segments are witnessing steady growth as healthcare systems increasingly rely on specialized diagnostic services and point-of-care testing. Rising demand for accurate confirmatory testing, routine disease screening, and decentralized healthcare services is contributing to the expansion of both segments.
The academic/research institutes segment is also growing steadily due to increasing research activities focused on emerging pathogens, vaccine development, and diagnostic innovation. Growing investments in infectious disease research and public health surveillance continue to support demand for advanced testing technologies across research institutions.
Speak to an Analystto discuss market opportunities.
North America infectious disease testing market accounted for 41.2% of the global market, reaching USD 11.54 billion in 2025, and is projected to grow at a CAGR of 7.35% during the forecast period. Strong healthcare infrastructure, increasing demand for rapid diagnostic tests, and rising investments in molecular diagnostics continue to drive regional market growth. Growing awareness of early disease detection and continuous technological advancements are further supporting market expansion.
The U.S. market was valued at USD 9.81 billion in 2025, making it the largest contributor in North America. Rising prevalence of infectious diseases, increasing adoption of advanced diagnostic technologies, and expanding public health initiatives continue to strengthen market growth.
Canada's market reached USD 1.73 billion in 2025. Growing healthcare investments, increasing laboratory testing capacity, and rising demand for accurate diagnostic solutions continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe infectious disease testing market accounted for 27.4% of the global market, reaching USD 7.67 billion in 2025, and is expected to register a CAGR of 6.92% during the forecast period. Increasing government support for disease surveillance, expanding diagnostic laboratories, and growing adoption of advanced testing technologies are driving regional growth. Continuous investments in healthcare infrastructure are also contributing to market development.
Germany's market accounted for USD 2.22 billion in 2025. Strong diagnostic infrastructure, increasing research activities, and rising demand for molecular testing continue to support market growth.
The UK market was valued at USD 1.53 billion in 2025. Growing investments in public health programs, increasing laboratory capacity, and rising demand for rapid diagnostic tests continue to contribute to market expansion.
Asia Pacific infectious disease testing market accounted for 22.6% of the global market, valued at USD 6.33 billion in 2025, and is projected to register a CAGR of 9.48% during the forecast period. Expanding healthcare infrastructure, increasing population, rising awareness of early disease detection, and growing government investments in diagnostic services continue to accelerate regional market growth.
Japan's market generated USD 1.14 billion in 2025. Increasing adoption of advanced diagnostic technologies, expanding healthcare services, and strong focus on disease surveillance continue to support market growth.
China's market accounted for USD 3.29 billion in 2025, representing the largest share within Asia Pacific. Expanding diagnostic manufacturing capacity, growing healthcare expenditure, and increasing demand for rapid infectious disease testing continue to drive market expansion.
Latin America infectious disease testing market accounted for 5.1% of the global market, reaching USD 1.43 billion in 2025, and is projected to grow at a CAGR of 7.76% during the forecast period. Improving healthcare access, increasing government initiatives for disease control, and expanding diagnostic laboratory networks continue to support regional market growth.
Brazil's market reached USD 0.73 billion in 2025. Rising investments in diagnostic services, increasing awareness of infectious disease screening, and expanding healthcare infrastructure continue to create growth opportunities across the country.
Middle East & Africa infectious disease testing market accounted for 3.7% of the global market, totaling USD 1.04 billion in 2025, and is anticipated to grow at a CAGR of 7.21% during the forecast period. Increasing healthcare investments, improving diagnostic capabilities, and growing focus on infectious disease surveillance are supporting regional market growth.
The UAE market was valued at USD 0.37 billion in 2025. Government initiatives to strengthen healthcare infrastructure, increasing adoption of advanced diagnostic technologies, and rising investments in disease monitoring programs continue to drive market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com